Restricted accessCase reportFirst published online 2015-2
Successful treatment of severe thrombocytopenia with the use of thrombopoeitin receptor agonist eltrombopag in a patient with chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia (CMML) is a clonal disorder of hematopoietic stem cells often occurring in elderly patients. The combination of CMML with autoimmune manifestations, including immune-mediated thrombocytopenia, has been described before in a number of case reports. To our knowledge, this is the first reported case of the successful treatment of CMML-related thrombocytopenia with a thrombopoeitin receptor agonist, eltrombopag.
De HollandaABeucherAHenrionD. Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res2011; 63: 1188–1194.
SaifMWHopkinsJLGoreSD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma2002; 43: 2083–2092.
4.
EnrightHJacobHSVercellottiG. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol1995; 91: 403–408.
5.
EnrightHMillerW. Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma1997; 24: 483–489.
6.
BusselJBChengGSalehMN. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med2007; 357: 2237–2247.
7.
GauchanDShaabanHGedeonD. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome. Ann Hematol, Epub ahead of print, 2014, pp. 1–2.
